TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Not Specified
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dianthus Therapeutics, a clinical-stage biotech company focused on severe autoimmune diseases, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Marino Garcia will present a corporate overview and meet with investors. The company is also advancing its lead candidate LBL-047 (DNTH212), a bifunctional fusion protein for systemic lupus erythematosus, into Phase 1 trials.

Insights
DNTH   positive

The company is advancing its pipeline with Phase 1 trial initiation for a lead candidate and securing speaking opportunities at a major industry conference, demonstrating progress and investor engagement in the competitive biotech space.